Bayer makes €250 million manufacturing investment in Finland
The company expects to complete its building and modernising plans in Turku by 2025
Bayer has announced a €250 million plan to build a new pharmaceutical facility in Turku, Finland, and, at the same time, upgrade an existing production plant.
The new production plant will be built in an existing building in Turku's Artukainen district, where the company already has operations. The plant is due to be completed by 2025, and has been billed by the company as "one of the most modern," using automation and robotics "extensively".
According to Jennifer Hunt, Head of the Product Supply Center Turku, the new facility's layout will improve the company's efficiency through optimised material and personnel flows.
The company's investment is also covering plans to update its existing plant, which was established in the 1960s and produces the contraceptive hormonal coil product family - Bayer's third best-selling pharmaceutical product globally.
Currently, Bayer employs more than 1,000 people in Finland. Despite the COVID-19 pandemic, the company hired almost 150 new staff last year.
Miriam Holstein, CEO of Bayer Nordic said that to meet growing demand, the company intends to tap into the country's "high level of education" and "highly skilled workforce" in the near future to make it the center of expertise for polymer-based technology and clinical trials.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.